• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor
    Hero Background

    Targeted Liposomes Drug Delivery Market

    ID: MRFR/Pharma/7284-HCR
    90 Pages
    Kinjoll Dey
    October 2025

    Targeted Liposomes Drug Delivery Market By Type (Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and others), Application (Fungal Infection Therapy, Cancer Therapy, and others) and Region (Americas, Europe, Asia-Pacific, and the Middle East & Africa) - Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Targeted Liposomes Drug Delivery Market Infographic
    Purchase Options

    Targeted Liposomes Drug Delivery Market Summary

    As per Market Research Future Analysis, the Targeted Liposomes Drug Delivery Market was valued at USD 2.48 Billion in 2023 and is projected to grow to USD 4.93 Billion by 2032, with a CAGR of 7.97% from 2024 to 2032. The market is driven by the increasing prevalence of chronic diseases, rising demand for targeted drug delivery, and innovations in liposomal technology. Recent advancements include the launch of new targeted liposome systems aimed at enhancing drug delivery efficacy while minimizing side effects. The Americas is expected to dominate the market due to strategic initiatives by key players, while the Asia-Pacific region is anticipated to be the fastest-growing market.

    Key Market Trends & Highlights

    Key trends influencing the Targeted Liposomes Drug Delivery Market include technological advancements and increasing disease prevalence.

    • Market Size in 2023: USD 2.48 Billion
    • Projected Market Size by 2032: USD 4.93 Billion
    • CAGR from 2024 to 2032: 7.97%
    • Fastest-growing region: Asia-Pacific

    Market Size & Forecast

    2023 Market Size USD 2.48 Billion
    2024 Market Size USD 2.67 Billion
    2032 Market Size USD 4.93 Billion

    Major Players

    Catalent (US), Pacira Pharmaceuticals, Inc. (US), Baxter (US), Lonza (Switzerland), Evonik (Germany), Merck KGaA (Germany), Fareva (France), Vetter (Germany), Polymun Scientific Immunbiologische Forschung GmbH (Austria), Recipharm AB (Sweden), Dalton Pharma Services (Canada)

    Targeted Liposomes Drug Delivery Market Drivers

    Market Growth Projections

    The Global Targeted Liposomes Drug Delivery Market Industry is projected to experience substantial growth over the coming years. The market is expected to expand from 2.67 USD Billion in 2024 to 6.21 USD Billion by 2035, indicating a robust CAGR of 7.97% from 2025 to 2035. This growth trajectory reflects the increasing adoption of targeted drug delivery systems across various therapeutic areas, including oncology, infectious diseases, and autoimmune disorders. The rising demand for effective and safe treatment options is likely to drive further investments in research and development, leading to the introduction of innovative liposomal formulations that cater to diverse patient needs.

    Rising Demand for Targeted Therapies

    The Global Targeted Liposomes Drug Delivery Market Industry is experiencing a surge in demand for targeted therapies, driven by the increasing prevalence of chronic diseases such as cancer and cardiovascular disorders. This shift towards precision medicine emphasizes the need for drug delivery systems that can selectively target diseased tissues while minimizing side effects. As a result, the market is projected to grow from 2.67 USD Billion in 2024 to 6.21 USD Billion by 2035, reflecting a compound annual growth rate (CAGR) of 7.97% from 2025 to 2035. This trend underscores the importance of innovative drug delivery mechanisms in enhancing therapeutic efficacy and patient outcomes.

    Growing Awareness of Personalized Medicine

    There is a growing awareness of personalized medicine within the Global Targeted Liposomes Drug Delivery Market Industry, which is reshaping treatment paradigms. Patients and healthcare providers increasingly recognize the benefits of tailored therapies that consider individual genetic profiles and disease characteristics. This shift is prompting pharmaceutical companies to invest in targeted liposome technologies that can deliver drugs more effectively to specific patient populations. As personalized medicine continues to gain traction, the demand for targeted liposomal formulations is likely to rise, contributing to the overall growth of the market. This trend aligns with the broader movement towards individualized healthcare solutions.

    Increasing Investment in Pharmaceutical R&D

    The Global Targeted Liposomes Drug Delivery Market Industry is benefitting from a notable increase in investments in pharmaceutical research and development. Governments and private entities are allocating substantial funds to explore novel drug delivery systems, including targeted liposomes. This financial support is crucial for advancing clinical trials and bringing innovative therapies to market. For example, various countries are implementing initiatives to foster collaboration between academia and industry, enhancing the development of targeted liposomal formulations. As a result, the market is expected to witness significant growth, driven by the introduction of new products and therapies that leverage targeted liposome technology.

    Advancements in Liposomal Formulation Technologies

    Innovations in liposomal formulation technologies are significantly influencing the Global Targeted Liposomes Drug Delivery Market Industry. Recent advancements, including the development of novel lipid compositions and encapsulation techniques, have improved the stability and bioavailability of liposomal drugs. These enhancements facilitate the effective delivery of therapeutic agents, particularly in oncology and infectious diseases. For instance, the introduction of pH-sensitive liposomes has shown promise in releasing drugs in acidic tumor microenvironments, thereby increasing therapeutic effectiveness. Such technological progress not only boosts the efficacy of existing treatments but also paves the way for the development of new liposomal formulations, further driving market growth.

    Regulatory Support for Innovative Drug Delivery Systems

    Regulatory bodies are increasingly supporting the development of innovative drug delivery systems, including targeted liposomes, within the Global Targeted Liposomes Drug Delivery Market Industry. Streamlined approval processes and guidelines for novel formulations are encouraging pharmaceutical companies to invest in research and development. This regulatory environment fosters innovation and expedites the introduction of new therapies to the market. For instance, initiatives aimed at fast-tracking the approval of breakthrough therapies are particularly beneficial for targeted liposomal drugs, which often address unmet medical needs. Such supportive regulatory frameworks are likely to enhance market growth by facilitating the timely availability of advanced drug delivery solutions.

    Key Companies in the Targeted Liposomes Drug Delivery Market market include

    Industry Developments

    October 2023: Nanobiotix announces the launch of its new NBTXR3 targeted liposome drug delivery system. NBTXR3 is designed to deliver the drug doxorubicin to cancer cells more effectively, while reducing the side effects of chemotherapy. NBTXR3 targeted liposome drug delivery systemOpens in a new windowStealth BioTherapeutics announces the launch of its new TriSpiration™ targeted liposome drug delivery system. TriSpiration™ is designed to deliver multiple drugs to cancer cells simultaneously, which can improve the efficacy of cancer treatment. TriSpiration™ targeted liposome drug delivery systemOpens in a new windowAvidity Biosciences announces the launch of its new ARC-101 targeted liposome drug delivery system.

    ARC-101 is designed to deliver the drug doxorubicin to cancer cells more effectively, while also delivering a second drug that inhibits tumor resistance. 

    September 2023: The FDA approves Nanobiotix's NBTXR3 targeted liposome drug delivery system for the treatment of soft tissue sarcoma. This is the first FDA-approved targeted liposome drug delivery system for the treatment of cancer. The European Medicines Agency (EMA) grants orphan drug designation to Stealth BioTherapeutics' TriSpiration™ targeted liposome drug delivery system for the treatment of triple-negative breast cancer. This designation gives Stealth BioTherapeutics access to funding and support from the EMA to accelerate the development of TriSpiration™.

    Avidity Biosciences announces that it has raised $100 million in Series A funding to support the development of its ARC-101 targeted liposome drug delivery system. This funding will help Avidity Biosciences to advance ARC-101 into clinical trials.

    Future Outlook

    Targeted Liposomes Drug Delivery Market Future Outlook

    The Global Targeted Liposomes Drug Delivery Market is projected to grow at a 7.97% CAGR from 2024 to 2035, driven by advancements in nanotechnology, increasing prevalence of chronic diseases, and rising demand for personalized medicine.

    New opportunities lie in:

    • Develop novel liposomal formulations targeting specific cancer types for enhanced therapeutic efficacy.
    • Leverage AI-driven analytics to optimize liposome design and improve drug delivery efficiency.
    • Expand partnerships with biotech firms to innovate combination therapies using targeted liposomes.

    By 2035, the market is expected to achieve substantial growth, positioning itself as a cornerstone of advanced therapeutic strategies.

    Report Scope

    Report Attribute/Metric Details
    Market Size 2023 2.48 (USD Billion)
    Market Size 2024 2.67 (USD Billion)
    Market Size 2032 NA (USD Billion)
    Compound Annual Growth Rate (CAGR) 7.97 % (2024 - 2032)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2023
    Market Forecast Period 2024 - 2032
    Historical Data 2019 - 2023
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Catalent (US), Pacira Pharmaceuticals, Inc. (US), Baxter (US), Lonza (Switzerland), Evonik (Germany), Merck KGaA (Germany), Fareva (France), Vetter (Germany), Polymun Scientific Immunbiologische Forschung GmbH (Austria), Recipharm AB (Sweden) and Dalton Pharma Services (Canada)
      Key Market Opportunities   The targeted liposomes drug delivery systems have played a significant role in the formulation of a potent drug to improve therapeutic outcomes in patients
      Key Market Drivers Increased demand for targeted drug delivery Increasing adoption of novel therapeutic approaches Growing prevalence of chronic diseases such as cancer and fungal infections

    Market Highlights

    Author
    Kinjoll Dey
    Research Analyst Level I

    He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

    Leave a Comment

    FAQs

    What is the estimated market value of the global targeted liposomes drug delivery market?

    Global targeted liposomes drug delivery market is expected to record a substantial market valuation of USD 4.92 Billion by 2032.

    What is the projected growth rate of the global targeted liposomes drug delivery market?

    Global targeted liposomes drug delivery market is projected to register a moderate 7.97% CAGR in the forecast period.

    Which type segment is expected to witness the highest growth?

    The Liposomal Doxorubicin segment is touted to observe substantial demand over the review period.

    What is the application segment of the global targeted liposomes drug delivery market expected to witness the highest growth?

    The fungal infection therapy segment is slated to mature as the fastest-growing segment.

    Who are the significant players operative in the global targeted liposomes drug delivery market?

    A few eminent market players functioning in the global targeted liposomes drug delivery market are Baxter (US), Lonza (Switzerland), Evonik (Germany), among others.

    Download Free Sample

    Kindly complete the form below to receive a free sample of this Report

    Case Study
    Chemicals and Materials